Minaris Regenerative Medicine LLC

WEST COLUMBIA, S.C., Oct. 24, 2023 /PRNewswire/ -- Nephron Pharmaceuticals Corporation today announced the new hiring of six key executives. Laura Friendly, Chief Accounting Officer Lori Aleshin, Head of Quality, Nephron 503B Outsourcing Facility Scott Bobbitt, Site Head of Quality, Nephron Pharmaceuticals Mike Kimple, Vice President of Operational Excellence Eric Cochran, Senior Director of Quality Operations David O'Connell, Quality Operations Clean Room Senior Manager Continue Reading From left to right: Laura Friendly, Lori Aleshin, Scott Bobbitt, Mike Kimple, Eric Cochran, David O’Connell "The industry knowledge and experience among this group is unmatched," said Nephron CEO and Owner Lou Kennedy. "We could not be prouder that a group of this caliber is as excited as we are about the future of Nephron. They are committed to delivering life-saving medications to patients, and we are confident they are equipped with all the tools needed to build on our momentum and keep Nephron growing." Laura Friendly, Chief Accounting Officer Laura Friendly is a certified public accountant with over 20 years of financial and strategic analysis experience. Before joining the Nephron team, Friendly was the Vice President of Finance at MPZ Holdings, LLC, where she led the accounting department responsible for the financial operation of over 40 Marco's Pizza locations. She has served as Chief Financial Officer at AVANTech, LLC and the Engineering Design & Testing Corp. Friendly received her Master of Business Administration and Bachelor of Science in Accounting from the University of South Carolina. Lori Aleshin, Head of Quality, 503B Outsourcing Facility Lori Aleshin has proven success in developing quality standards, policies, and procedures across pharmaceutical and medical device industries. Before her role as Head of Quality for Nephron 503B Outsourcing Facility, Aleshin worked as Director of Quality for Athenex Inc. Pharmaceuticals, where she directly managed senior quality managers, engineers and oversaw 30 indirect quality control and microbiology laboratories, as well as all quality assurance employees. She has served in director-level roles at Ivoclar Vivadent Inc., where she successfully obtained Medical Device Single Audit Program Certification on her first application, and Safetec of America Inc. Aleshin earned her Master of Public Administration in healthcare management from Keller Graduate School of Management, her Master of Business Administration in Finance from Keller Graduate School of Management and her Bachelor of Science in Chemistry from Southern Arkansas University. Scott Bobbitt, Site Head of Quality, Nephron Pharmaceuticals Scott Bobbitt brings to Nephron a comprehensive background in quality assurance management in the areas of R&D and commercialization for the pharmaceutical industry. Before joining the Nephron team, Bobbitt served as vice president of quality for Adicet Bio Inc., where he was responsible for assuring the quality and compliance of cell, gene and CAR-T manufacturing, testing and distribution practices. Throughout his 30-year career, he has held key roles in quality assurance at organizations including Hitachi Chemicals Advanced Therapeutics Solutions, Dermira, Inc. and Novartis Pharmaceuticals Corporation. Bobbitt earned his Bachelor of Science in Business Administration from North Carolina Wesleyan College and is currently pursuing a Master of Science in Quality Assurance at Southern Polytechnic State University. Mike Kimple, Vice President of Operational Excellence During his nearly 30-year career, Mike Kimple has been responsible for the development, construction, operation and maintenance of the major multinational personal protective equipment (PPE) corporation, The Showa Group. As Americas Director of Manufacturing, he supervised the efforts of more than 700 employees for the operation, maintenance and expansion of three ISO-certified facilities. He held multiple management roles at the PPE manufacturer, where he oversaw the architectural design of its research and development center. Kimple received his Bachelor of Science in Biomedical Engineering from Vanderbilt University. Eric Cochran, Senior Director of Quality Operations Eric Cochran joins Nephron with 25 years of manufacturing and quality assurance experience in biopharmaceutical and medical device environments producing sterile and non-sterile products. In his previous role as Senior Director of Manufacturing Quality Assurance at Glenmark Pharmaceuticals, he led a team of 14 responsible for all aspects of quality assurance and acted as an in-process quality assurance expert for the microbiology and chemistry laboratory activities, including all current Good Manufacturing Practices (cGMP). Cochran earned his Bachelor of Science in Chemical Engineering from Iowa State University. David O'Connell, Quality Operations Clean Room Senior Manager David O'Connell is a microbiology professional who has successfully recruited, managed, and led comprehensive environmental monitoring training for production personnel on aseptic techniques, behaviors, set-up, and equipment operation. Before joining the Nephron team, he served as a consultant for Pfizer at its McPherson, Kansas location, where he used MODA systems to improve the efficiency of daily operations. O'Connell has used his MODA expertise to train employees and implement its workflows at Charles River Laboratories and PCT Cell Therapy Services, developing teams with quality control best practices. O'Connell received his Associate Degree in Criminal Justice from Union College. A West Columbia, S.C.-based company, Nephron develops and produces safe, affordable generic inhalation solutions and suspension products. The company also operates an industry-leading 503B Outsourcing Facility division which produces pre-filled sterile syringes, luer-lock vials, IV bottles and IV bags for hospitals across America, in an effort to alleviate drug shortage needs. For more information, please visit . CONTACT: Connor Watkins, cwatkins@nephronpharm.com SOURCE Nephron Pharmaceuticals Corporation

TAMPA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) announced the appointments of Bruce Cassidy and John Gandolfo to the Board of Directors effective October 4, 2023. “We are delighted to welcome Bruce Cassidy and John Gandolfo to the Oragenics Board,” said Charlie Pope, Chairman of Oragenics. “Bruce’s deep experience in high-technology global businesses will be invaluable to Oragenics as we grow our portfolio. John’s proven leadership in the life sciences, capital raising and financial management will be critical to our future. We are confident that Bruce and John will provide valuable perspectives as we continue to execute our strategy, pursue our mission to serve patients and enhance value for all Oragenics’ shareholders.” Mr. Cassidy currently serves on the boards for various companies, including as Chairman of the Board of each of Loop Media, Inc., KeyStar Corp, Arboreta Healthcare, Inc., Selinsky Force, LLC and The Sarasota Green Group. He was also the founding investor and served on the board of directors of Ohio Legacy Corp. Previously, Mr. Cassidy was the founder and Chief Executive Officer (CEO) of Excel Mining Systems from 1991 until its sale in 2007 to Orica Mining Services, and from 2008 to 2009, served as the President and CEO of one of its subsidiaries, Minova North & South Americas. He is currently the President of The Concession Golf Club in Sarasota, Florida. “I am excited to be a part of the next generation of drug and delivery technologies for critical unmet medical needs. The unique platform of formulas and the nasal application of delivering novel therapeutics represents the future of neurological drugs. I look forward to working with the Oragenics Board and the Odyssey team to help steer the new strategy and direction of the Company,” said Bruce Cassidy. Mr. Gandolfo has more than 30 years of experience as a Chief Financial Officer (CFO) of multiple rapidly growing private and publicly held companies with a primary focus in the life sciences, healthcare and medical device areas. Mr. Gandolfo has had direct responsibility over all financial and treasury functions including capital raising and mergers and acquisitions. Mr. Gandolfo currently serves as CFO of Eyenovia, Inc., (EYEN) a late-stage ophthalmic biopharmaceutical company since January 2018. Prior to this, Mr. Gandolfo was CFO of Xtant Medical Holdings, Inc., a biologics company, from July 2010 through September 2017. Prior to this, he served as the CFO for Progenitor Cell Therapy LLC from January 2009 to June 2010 and, before that, as CFO of Power Medical Interventions, Inc. from January 2007 to January 2009. Mr. Gandolfo currently serves on the Board of Directors of Electrocore, Inc. (ECOR) and previously served on the Board of Directors and was chair of the Audit Committee of Odyssey Health, Inc. f/k/a Odyssey Group International, Inc., (ODDY) from 2019 until 2023. Oragenics announced the signing of an asset purchase agreement with Odyssey Health on October 6, 2023. “Having been involved with the Odyssey team for the past few years I am a strong believer in the technology and the synergies with Oragenics. I am happy to continue my involvement as a member of Oragenics Board,” said John Gandolfo. Mr. Gandolfo is currently a member of the Board of Directors of Electrocore, Inc. (ECOR) and is chair of the Compensation Committee and sits on their audit committee. Mr. Gandolfo received his B.A. degree in Business Administration from Rutgers University. About Oragenics Oragenics, Inc. is a development-stage company focused on nasal delivery of pharmaceutical medications including in neurology and fighting infectious diseases including coronaviruses and multidrug-resistant organisms. Its lead product is NT-CoV2-1, an intranasal vaccine candidate to prevent COVID-19 and variants of the SARS-CoV-2 virus. The NT-CoV2-1 program leverages coronavirus spike protein research licensed from the National Institutes of Health (NIH) and the National Research Council of Canada (NRC) with a focus on reducing viral transmission and offering a more patient-friendly intranasal administration. Its lantibiotics program features a novel class of antibiotics against bacteria that have developed resistance to commercial antibiotics. For more information, please visit . Forward-Looking Statements This communication contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding: the ability of Odyssey and Oragenics to successfully close their asset purchase agreement; the ability of the Oragenics to timely and successfully achieve the anticipated benefits of acquiring the Odyssey assets; Oragenics’ future performance, business prospects, events and product development plans. These forward-looking statements are based on management’s beliefs and assumptions and information currently available. The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “project” and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to, the following: Oragenics’ ability increase its authorized shares of Common Stock; Oragenics’ ability to obtain a quorum at future shareholders meetings; Oragenics’ ability to obtain its shareholders’ approval for the (a) the increase in Oragenics’ authorized Common Stock from 4,166,666 to 350,000,000 and (b) the conversion of the Series F Preferred Stock into Common Stock; whether or not all of the closing conditions to the Odyssey transaction will be satisfied and otherwise whether Oragenics will be able to successfully close the Odyssey transaction; Oragenics’ ability to obtain necessary funding, non-dilutive or otherwise, for the development of its product candidates, including its vaccine and lantibiotic assets and, if the Odyssey transaction successfully closes, the concussion asset; Oragenics’ ability to advance the development of its vaccine candidate and lantibiotics candidate (and, if the Odyssey transaction successfully closes, the concussion asset) under the timelines and in accord with the milestones it projects; the regulatory application process, research and development stages, and future clinical data and analysis relating to vaccines and lantibiotics, including any meetings, decisions by regulatory authorities, such as the FDA and Canadian regulatory authorities and investigational review boards, whether favorable or unfavorable; the potential application of Oragenics’ vaccine candidate to variants and other coronaviruses; Oragenics’ ability to obtain, maintain and enforce necessary patent and other intellectual property protection and license agreements; the nature of competition and development relating to COVID-19 immunization and therapeutic treatments and demand for vaccines and antibiotics; Oragenics’ and/or Odyssey’s expectations as to the outcome of preclinical studies, nasal administration, transmission, manufacturing, storage and distribution; other potential adverse impacts such as delays in regulatory review, manufacturing delays and supply chain issues, adverse impacts on healthcare systems and disruption of the global economy; the ability to sustain compliance with Oragenics’ exchange listing requirements; and general economic and market conditions and risks, as well as other uncertainties described in our filings with the U.S. Securities and Exchange Commission. All information set forth in this press release is as of the date hereof. You should consider these factors in evaluating the forward-looking statements included in this press release and not place undue reliance on such statements. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by law.

Dublin, May 11, 2023 /PRNewswire/ -- The "Global Stem Cell Partnering Terms and Agreements 2010-2023" report has been added to ResearchAndMarkets.com's offering. The Global Stem Cell Partnering Terms and Agreements 2010-2023 report provides comprehensive understanding and unprecedented access to the stem cell partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in stem cell partnering Partnering agreement structure Partnering contract documents Top deals by value Most active dealmakers Average deal terms for stem cells The report provides a detailed understanding and analysis of how and why companies enter stem cell partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes. This report provides details of the latest stem cell agreements announced in the life sciences since 2010. The report takes the reader through a comprehensive review stem cell deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering stem cell partnering deals. The report presents financial deal term values for stem cell deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals. The middle section of the report explores the leading dealmakers in the stem cell partnering field; both the leading deal values and most active stem cell dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market. One of the key highlights of the report is that over 700 online deal records of actual stem cell deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not. The initial chapters of this report provide an orientation of stem cell dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in stem cell dealmaking since 2010, including details of headline, upfront, milestone and royalty terms. Chapter 3 provides a review of the leading stem cell deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 4 provides a comprehensive listing of the top 25 most active companies in stem cell dealmaking with a brief summary followed by a comprehensive listing of stem cell deals announced by that company, as well as contract documents, where available. Chapter 5 provides a comprehensive and detailed review of stem cell partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand. Chapter 6 provides a comprehensive and detailed review of stem cell partnering deals signed and announced since Jan 2010. The chapter is organized by specific stem cell technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand. A comprehensive series of appendices is provided organized by stem cell partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand. The report also includes numerous tables and figures that illustrate the trends and activities in stem cell partnering and dealmaking since 2010. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of stem cell technologies and products. Key benefits Global Stem Cell Partnering Terms and Agreements 2010-2023 provides the reader with the following key benefits: In-depth understanding of stem cell deal trends since 2010 Access to headline, upfront, milestone and royalty data Detailed access to actual stem cell contracts entered into by leading biopharma companies Identify most active stem cell dealmakers since 2010 Insight into terms included in a stem cell partnering agreement, with real world examples Understand the key deal terms companies have agreed in previous deals Undertake due diligence to assess suitability of your proposed deal terms for partner companies Report scope Global Stem Cell Partnering Terms and Agreements 2010-2023 is intended to provide the reader with an in-depth understanding and access to stem cell trends and structure of deals entered into by leading companies worldwide. Stem Cell Partnering Terms and Agreements includes: Trends in stem cell dealmaking in the biopharma industry since 2010 Access to headline, upfront, milestone and royalty data Access to stem cell contract documents Leading stem cell deals by value since 2010 Most active stem cell dealmakers since 2010 In Global Stem Cell Partnering Terms and Agreements 2010-2023, the available deals are listed by: Company A-Z Headline value Stage of development at signing Deal component type Specific therapy target Technology type Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The Global Stem Cell PartneringTerms and Agreements 2010-2023 report provides comprehensive access to available deals and contract documents for over 700 stem cell deals. Analyzing actual contract agreements allows assessment of the following: What are the precise rights granted or optioned? What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Companies Mentioned Regenetech Regeneus Stempeutics Bakulev Center of Cardiovascular Surgery of Russian Academy of Sciences CNA Development The New York Stem Cell Foundation Arthrex Generex Biotechnology Celltex Therapeutics Viscofan BioEngineering Dana-Farber Cancer Institute Biosafe BioLife Solutions Rockefeller University Montefiore Medical Center Wake Forest University Fast Forward Jain Foundation Promega Lineage Cell Therapeutics Hepregen Histogen Lentigen Philogen Vascugen Shenogen Pharma VistaGen Therapeutics Centogene Spinogenix Transgenomic Biological Industries Procognia Apceth Munich Technical University Lehigh University Monash University Abu Dhabi Stem Cells Center Shanghai Cell Therapy Group Shanghai Jia Fu Medical Apparatus Sinopharm AXM Pharma For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets